Our mission is to fix the broken clinical-stage biopharma model by in-licensing therapeutic assets and developing them through integrated, technology-first clinical trial infrastructure. We are a new initiative built on a proven foundation, with a team that has delivered 40+ trials across the US and Europe, and we are a high-growth, mission-driven, VC-funded startup.
Own CMC oversight across every active asset, ensuring on-time and on-budget delivery of drug substance, drug product, analytics, stability, and regulatory filings.
Select, contract, and manage CDMOs and external partners, holding them to timelines, quality, and cost.
Scope and de-risk the CMC of inherited in-licensing candidates, flagging manufacturing complexity or cost that could affect asset viability.